Skip to main content
Equibles
PLRX logo

PLRX · Pliant Therapeutics, Inc.

Track PLRX — free

Use PLRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.16 +0.03 (+2.65%) At close · Sep 4
Rebalance outlook locked
Market Cap
$69.97M
Shares
61.92M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.16 Open$1.12 Day$1.11–1.19 52W close$1.03–1.87 Avg vol 30d396K Short int2.8M · 4.5% float · 7.7d Short vol47% DataJun 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$92.29M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-101.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$158.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-28.8%
Trailing year
Short interest
4.5%
Latest settlement · 7.7 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −5%
below
Price vs 50-day avg +5%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 15%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +10%
trailing
6-month return −11%
trailing
YTD return −5%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.47% of float · ▼ -1.3% MoM · 7.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
EPS growth +30%
Y/Y
Free cash flow $-128.7M
Balance sheet $45.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −45%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−5% Bearish
Price vs 50-day avg
+5% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
15% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.47% of float · ▼ -1.3% MoM · 7.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 15% Range high $2
vs 200-day avg -5% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PLRX
Pliant Therapeutics, Inc.
this stock
$69.97M -4.9% — — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +20.5% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.84B +7.2% +20.8% 20.9 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
86
% held
77.9%
Net QoQ
-1.6M sh
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
31
View
Short & Settlement
Short Interest Falling
Shares short
2.8M
Days to cover
7.7d
Change
-37.9K sh
View
Short Volume
Short vol %
47%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
4
Value
$4
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
57.3%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-149.3M
EPS diluted
$-2.43
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
12
View
Proposed Sales
Value
$113.2K
Shares
10.2K
Filed
Jan 22, 2025
View
Exempt Offerings
Offering
$100.4M
Filed
Mar 11, 2020
View

Performance

5D 20D 120D MTD YTD
PLRX +4.5% +10.5% -11.5% +5.5% -4.9%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +4.4% +10.9% -26.6% +5.0% -17.9%
Key facts CIK 1746473 CUSIP 729139105 13F (30d) 81 filings 81 filers Visit website Investor relations